spacer
home > pmps > autumn 2017 > high demands
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

High Demands

As early as 1747, the Scottish marine physician James Lind conducted a controlled comparative study on the treatment of scurvy. At that time, he was neither interested in randomised trial design, ethical principles nor legal norms. Over the following centuries, the complexity of clinical trials steadily grew, from the development of statistical methods to multinational alignment with current regulatory frameworks such as Annex VI (1). Additionally, today's companion diagnostics, orphan drugs and, above all, biopharmaceuticals require further measures in terms of quality, efficiency and safety. Biotechnology products are critical in that respect, but they are expensive and complicated to manufacture, require low temperatures and are usually administered in prefilled syringes. These characteristics have to be taken into account by all participants in the modern trial supply chain by sponsors, CROs, contract manufacturing organisations, depots and sites, down to suppliers of secondary packaging.

Labelling of Biopharmaceuticals

However, due to the success of biotech products, this effort is paying off. According to a study conducted by the Tufts Center for the Study of Drug Development, biopharmaceuticals accounted for 35% of all new drug approvals in the US from 2006 through to 2016 (2). The FDA approved 225 new biotech products between 2000 and 2016, compared to 304 small-molecule drug authorisations during the same period. The annual pace of 13 new biotech product approvals accelerated to more than 20 per year between 2014 and 2016 (3). Accordingly, their market value already reached US$68 billion in 2016.

Demanding Labels
Clinical studies involving biotech products are a good example of growing complexity. New requirements are emerging for labelling. Only papers, films, adhesives and inks that are permanently temperature- and moisture-resistant are being used. Furthermore, prefilled syringes are becoming increasingly popular because they represent enhanced safety, accuracy and ease-of-use compared to conventional vial and ampoule packaging. This also explains why the clinical trials government database at the US Department of Health has recorded a steady rise in the use of prefilled syringes in trials (4). However, the space available for marking syringes is limited, which is why booklet or wrap-around labels are recommended for multinational trials where labelling has to contain all the national languages required by law. Thanks to partial neutralisation, these labels can be wrapped around syringes several times to create sufficient labelling space directly on investigational medical products (IMPs).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
As Business Development Manager for Faubel in Northern Europe, Anthony Morrow is based at the company’s central UK sales office in Northampton, covering the UK, Ireland and Scandinavia region. He is a qualified engineer with extensive background in product development. Since joining Faubel in 2014, Anthony's primary focus has been to build awareness for the firm’s capabilities in clinical trial labelling among prospective, existing and past clients. Furthermore, he is committed to improving business partnerships, while developing and maintaining substantial client relationships.
spacer
Anthony Morrow
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

RSSL introduces same-day mycoplasma testing service in UK

Reading Scientific Services Ltd (RSSL), a leading provider of scientific and technical solutions to the global biopharmaceutical, pharmaceutical, and biopharmaceutical sectors, has introduced the United Kingdom’s first same-day mycoplasma testing service for manufacturers of biologic medicines.
More info >>

White Papers

Faster, Better, Cheaper: Lean as a Driving Force Behind Pharmaceutical Companies’ Growth

TBM Consulting Group

The pharmaceutical industry faces countless challenges: patent expirations, weak product development pipelines, downward pricing pressure and an increasingly burdensome regulatory environment. The most important question for companies is now “How can we position ourselves optimally to be successful in the long term?” Some pharmaceutical companies used the economic downturn in 2009 to embrace measures in the fields of cost reduction and efficiency increases, which can be implemented at short notice. The continuous and consistent implementation of sustainable measures that guarantee stability and form the basis for future growth was not necessarily paramount within this.
More info >>

 
Industry Events

World Advanced Therapies & Regenerative Medicine Congress 2019

15-17 May 2019, Business Design Centre, London

The World Advanced Therapies & Regenerative Medicine Congress is an exhibition and conference that has grown to become one of the best and most established cell and gene events in the world today.     The 2019 edition will be in its 14th year and it continues to grow and attract a large audience of biotech, pharma, start-ups, investors, research and technology companies from around the world. The conference and exhibition will host over 1000 attendees, 250 speakers and 80 exhibition booths. Over 500 different global companies are represented every year at this event. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement